Inactive Instrument

Sierra Oncology, Inc.

Equities

SRRA

US82640U4040

Biotechnology & Medical Research

Sierra Oncology, Inc Announces Resignation of Nick Glover as President and Chief Executive Officer

May 26, 2020 at 07:08 am EDT

On May 22, 2020, Dr. Nick Glover, the President and Chief Executive Officer of Sierra Oncology, Inc. and member of the company’s Board of Directors, resigned from such roles effective as of the same date.

Latest news about Sierra Oncology, Inc.

Sierra Oncology, Inc. Announces Update on Sra737	23-03-06	CI
Sareum Holdings Says GSK Completes Acquisition of Sierra Oncology	22-07-04	DJ
Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from NASDAQ Composite Index	22-07-04	CI
Sierra Oncology, Inc. Announces Executive Changes	22-07-01	CI
GSK Completes $1.9 Billion Purchase of Sierra Oncology	22-07-01	MT
GlaxoSmithKline plc completed the acquisition of Sierra Oncology, Inc. from Frazier Healthcare VI, L.P., Frazier Life Sciences VIII, L.P., Frazier Life Sciences Public Fund, L.P., all managed by Frazier Management, L.L.C., and others.	22-06-30	CI
Sierra Oncology Shareholders Approve Acquisition by GSK	22-06-29	MT
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2500 Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2500 Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell Small Cap Completeness Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000 Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000E Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from Russell 3000E Value Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000E Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell Small Cap Comp Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Dynamic Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000 Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from Russell Microcap Value Index	22-06-24	CI
Sierra Oncology Submits New Drug Application to FDA for Cancer Treatment Momelotinib	22-06-17	MT
Sierra Oncology, Inc. Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration	22-06-17	CI
Pfizer to sell stake in GSK's consumer health business after it lists	22-06-01	RE
GSK to spend up to $3.3 bln on Affinivax to boost vaccines roster	22-05-31	RE
Sierra Oncology, Inc. Announces Momelotinib Pivotal Phase 3 Data Receives Oral Presentation At American Society of Clinical Oncology Annual Meeting	22-05-26	CI

Chart Sierra Oncology, Inc.

Duration

Period

More charts

Company Profile

Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company's lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+8.29%	113B
REGENERON PHARMACEUTICALS, INC.	+10.21%	106B
ARGENX SE	+0.41%	22.27B
BIONTECH SE	-11.90%	22.22B
GENMAB A/S	-5.99%	19.43B
WUXI APPTEC CO., LTD.	-37.36%	17.87B
BEIGENE, LTD.	-5.17%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.70%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.65%	12.52B

Bio Therapeutic Drugs